Samsung Biologics said March 25 it is taking part in DCAT Week 2026, being held March 23-26 (local time) in New York, to step up global contract-winning efforts.
With more than 130 years of history, DCAT Week is a global pharmaceutical and biotech networking event that began in 1890 under the New York Chamber of Commerce.
Samsung Biologics has attended the event for 11 consecutive years since 2016, except in 2020 when it was not held because of COVID-19.
The company said it set up a dedicated meeting room in a main location at the venue and plans to hold more than 50 business meetings with global drugmakers. CEO John Rim is also attending to discuss strategic partnerships with key industry figures.
On the first day of the event, March 23, Kevin Sharp, vice president in charge of sales and operations at the company’s sales center, spoke at a member company presentation forum. Only companies selected through DCAT screening can participate, and just 20 companies were given a chance to present this year.
Sharp shared recent results under the theme of expanding production capacity and developing networks, including the acquisition of a plant in Rockville, the purchase of land for a third Bio Campus, an open innovation partnership with Eli Lilly, and a vaccine manufacturing partnership with the Coalition for Epidemic Preparedness Innovations, or CEPI.
Samsung Biologics also worked to raise brand awareness. It joined a presentation session on March 24 as a co-sponsor and promoted its CDMO capabilities before and after the session. The company also installed banners and promotional materials at the venue.
At DCAT’s main gala dinner on March 26, Samsung Biologics will participate as a sponsor alongside global CDMO companies including Lonza and Thermo Fisher Scientific. The company said it plans to expand networking and build business partnerships with industry leaders attending the dinner.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.